Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1965 Jul;54(1):258–266. doi: 10.1073/pnas.54.1.258

A relationship between the hallucinogenic activity of drugs and their electronic configuration.

S H Snyder, C R Merril
PMCID: PMC285831  PMID: 5216361

Full text

PDF
258

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AXELROD J., BRADY R. O., WITKOP B., EVARTS E. V. The distribution and metabolism of lysergic acid diethylamide. Ann N Y Acad Sci. 1957 Mar 14;66(3):435–444. doi: 10.1111/j.1749-6632.1957.tb40739.x. [DOI] [PubMed] [Google Scholar]
  2. BALESTRIERI A., FONTANARI D. Acquired and crossed tolerance to mescaline, LSD-25, and BOL-148. AMA Arch Gen Psychiatry. 1959 Sep;1:279–282. doi: 10.1001/archpsyc.1959.03590030063008. [DOI] [PubMed] [Google Scholar]
  3. CERLETTI A., ROTHLIN E. Role of 5-hydroxytryptamine in mental diseases and its antagonism to lysergic acid derivatives. Nature. 1955 Oct 22;176(4486):785–786. doi: 10.1038/176785a0. [DOI] [PubMed] [Google Scholar]
  4. FABING H. D., HAWKINS J. R. Intravenous bufotenine injection in the human being. Science. 1956 May 18;123(3203):886–887. doi: 10.1126/science.123.3203.886. [DOI] [PubMed] [Google Scholar]
  5. GADDUM J. H. Serotonin-LSD interactions. Ann N Y Acad Sci. 1957 Mar 14;66(3):643-7; discussion, 647-8. doi: 10.1111/j.1749-6632.1957.tb40754.x. [DOI] [PubMed] [Google Scholar]
  6. ISBELL H., WOLBACH A. B., WIKLER A., MINER E. J. Cross tolerance between LSD and psilocybin. Psychopharmacologia. 1961;2:147–159. doi: 10.1007/BF00407974. [DOI] [PubMed] [Google Scholar]
  7. KAKIMOTO Y., ARMSTRONG M. D. On the identification of octopamine in mammals. J Biol Chem. 1962 Feb;237:422–427. [PubMed] [Google Scholar]
  8. KALIR A., SZARA S. SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF FLUORINATED TRYPTAMINE DERIVATIVES. J Med Chem. 1963 Nov;6:716–719. doi: 10.1021/jm00342a019. [DOI] [PubMed] [Google Scholar]
  9. KARREMAN G., ISENBERG I., SZENT-GYORGYI A. On the mechanism of action of chlorpromazine. Science. 1959 Oct 30;130(3383):1191–1192. doi: 10.1126/science.130.3383.1191. [DOI] [PubMed] [Google Scholar]
  10. NEFF N., ROSSI G. V., CHASE G. D., RABINOWITZ J. L. DISTRIBUTION AND METABOLISM OF MESCALINE-C14 IN THE CAT BRAIN. J Pharmacol Exp Ther. 1964 Apr;144:1–7. [PubMed] [Google Scholar]
  11. SZARA S., AXELROD J. Hydroxylation and N-demethylation of N, N-dimethyltryptamine. Experientia. 1959 Jun 15;15(6):216–217. doi: 10.1007/BF02158111. [DOI] [PubMed] [Google Scholar]
  12. Shulgin A. T. Psychotomimetic amphetamines: methoxy 3,4-dialkoxyamphetamines. Experientia. 1964 Jul 15;20(7):366–367. doi: 10.1007/BF02147960. [DOI] [PubMed] [Google Scholar]
  13. TURNER W. J., MERLIS S. Effect of some indolealkylamines on man. AMA Arch Neurol Psychiatry. 1959 Jan;81(1):121–129. doi: 10.1001/archneurpsyc.1959.02340130141020. [DOI] [PubMed] [Google Scholar]
  14. WEIL-MALHERBE H., BONE A. D. The effect of reserpine on the intracellular distribution of catecholamines in the brain stem of the rabbit. J Neurochem. 1959 Aug;4:251–263. doi: 10.1111/j.1471-4159.1959.tb13201.x. [DOI] [PubMed] [Google Scholar]
  15. WOLBACH A. B., Jr, MINER E. J., ISBELL H. Comparison of psilocin with psilocybin, mescaline and LSD-25. Psychopharmacologia. 1962;3:219–223. doi: 10.1007/BF00412109. [DOI] [PubMed] [Google Scholar]
  16. Woolley D. W., Shaw E. A BIOCHEMICAL AND PHARMACOLOGICAL SUGGESTION ABOUT CERTAIN MENTAL DISORDERS. Proc Natl Acad Sci U S A. 1954 Apr;40(4):228–231. doi: 10.1073/pnas.40.4.228. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES